Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 1026

Sort by

Sort Order Select

Journal Articles

How I treat pediatric acute myeloid leukemia

Jeffrey E. Rubnitz, Gertjan J. L. Kaspers

Blood (2021) 138 (12): 1009–1018.

https://doi.org/10.1182/blood.2021011694

Published: 2021

Journal Articles

Cryptic insertion of KMT2A , a rare t(9;11) variant

Nada Assaf, Christine Terré

Blood (2021) 137 (13): 1843.

https://doi.org/10.1182/blood.2020010442

Published: 2021

Journal Articles

CLEC12A and CD33 coexpression as a preferential target for pediatric AML combinatorial immunotherapy

Semjon Willier, Paula Rothämel, Maximilian Hastreiter, Jonas Wilhelm, Dana Stenger, Franziska Blaeschke, Meino Rohlfs, Theresa Kaeuferle, Irene Schmid, Michael H. Albert, Vera Binder, Marion Subklewe, Christoph Klein, Tobias Feuchtinger

Blood (2021) 137 (8): 1037–1049.

https://doi.org/10.1182/blood.2020006921

Published: 2021

Includes: Supplemental data

Journal Articles

Immunogenomic identification and characterization of granulocytic myeloid-derived suppressor cells in multiple myeloma

Blood (2020) 136 (2): 199–209.

https://doi.org/10.1182/blood.2019004537

Published: 2020

Includes: Supplemental data

Journal Articles

Mutational profile and benefit of gemtuzumab ozogamicin in acute myeloid leukemia

Blood (2020) 135 (8): 542–546.

https://doi.org/10.1182/blood.2019003471

Published: 2020

Includes: Supplemental data

Journal Articles

How I treat acute myeloid leukemia in the era of new drugs

Courtney D. DiNardo, Andrew H. Wei

Blood (2020) 135 (2): 85–96.

https://doi.org/10.1182/blood.2019001239

Published: 2020

Includes: Supplemental data

Journal Articles

Establishment of a Spontaneous Stromal Microenvironment from Cord Blood Supports Human Dynamic Erythropoietic Temporal Maturation in Long-Term Serum- and Cytokine-Free 3D Cultures and Reveals a Distinct CD44 hi Population

Susana Brito Dos Santos, MSc PhD, Athanasios Mantalaris, PhD, Nicki Panoskaltsis, MD PhD

Blood (2019) 134 (Supplement_1): 2219.

https://doi.org/10.1182/blood-2019-131085

Published: 2019

Journal Articles

Novel CD33 Antibodies Unravel Localization, Biology, and Therapeutic Implications of CD33 Isoforms

Mohammed Gbadamosi, BS, Tiffany A. Hylkema, BS, Soheil Meshinchi, MD PhD, Jatinder K Lamba, M.Sc., PhD

Blood (2019) 134 (Supplement_1): 908.

https://doi.org/10.1182/blood-2019-122596

Published: 2019

Journal Articles

Phase 1 First-in-Human Trial of AMV564, a Bivalent Bispecific (2:2) CD33/CD3 T-Cell Engager, in Patients with Relapsed/Refractory Acute Myeloid Leukemia (AML)

Peter Westervelt, MD PhD, Jorge E. Cortes, MD, Jessica K. Altman, Meixiao Long, MD, Vivian G. Oehler, MD, Ivana Gojo, MD, Jeanmarie Guenot, PhD, Patrick Chun, MD, Gail J. Roboz, MD

Blood (2019) 134 (Supplement_1): 834.

https://doi.org/10.1182/blood-2019-129042

Published: 2019

Journal Articles

Preliminary Results from a Phase 1 First-in-Human Study of AMG 673, a Novel Half-Life Extended (HLE) Anti-CD33/CD3 BiTE ® (Bispecific T-Cell Engager) in Patients with Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML)

Marion Subklewe, MD, Anthony Stein, MD, Roland B. Walter, MD PhD MS, Ravi Bhatia, MD, Andrew H. Wei, PhD FRACP, FRCPA, MBBS, David Ritchie, MD PhD, Veit Bücklein, MD, Pankit Vachhani, MD, Tian Dai, PhD, Antreas Hindoyan, PhD, Suresh Agarwal, PhD, Abraham Anderson, Sophia Khaldoyanidi, MD PhD, Farhad Ravandi, MD

Blood (2019) 134 (Supplement_1): 833.

https://doi.org/10.1182/blood-2019-127977

Published: 2019

Journal Articles

Characterization of Immune Cells Producing Regulatory Cytokines That Mediate Engraftment in Sickle Cell Disease Patients after Haploidentical Peripheral Blood Stem Cell Transplantation

Berline Francis, Arunakumar Gangaplara, PhD, Deepali K Bhat, PhD, J. Philip McCoy, PhD, Courtney D. Fitzhugh, MD

Blood (2019) 134 (Supplement_1): 803.

https://doi.org/10.1182/blood-2019-130711

Published: 2019

Journal Articles

Chimeric Antigen Receptor Modified Memory-like (CAR-ML) NK Cells Exhibit Potent Responses to NK-Resistant Tumors

Melissa M Berrien-Elliott, PhD, Margery Gang, Nancy M Marin Agudelo, PhD, Lynne M Marsala, Mark Foster, Carly Neal, B.S., Wong Pamela, B.S., Wei M Meng, B.S., Maximilian M Schaettler, B.S., Tim Schappe, BS, Todd A Fehniger, MD PhD

Blood (2019) 134 (Supplement_1): 869.

https://doi.org/10.1182/blood-2019-127546

Published: 2019

Journal Articles

Addition of the PARP Inhibitor, Talazoparib, to Gemtuzumab Ozogamicin Significantly Enhances Anti-Leukemic Activity in Human CD33+ Acute Myeloid Leukemia

Scott M. Portwood, MBA, MS, Marianna C Cantella, BE, Tara L. Cronin, BA, Eunice S. Wang, MD

Blood (2019) 134 (Supplement_1): 1371.

https://doi.org/10.1182/blood-2019-130427

Published: 2019

Journal Articles

Preliminary Lasso Regression Analysis Identifies DNA-Damage Gene Expression Signature Predictive of Clinical Outcomes in Patients Using Gemtuzumab Ozogamicin

Mohammed Gbadamosi, BS, Abdelrahman H. Elsayed, MSc, Rhonda E. Ries, MA, Soheil Meshinchi, MD PhD, Jatinder K Lamba, M.Sc., PhD

Blood (2019) 134 (Supplement_1): 1401.

https://doi.org/10.1182/blood-2019-131210

Published: 2019

Journal Articles

Checkpoint Blockade in Combination with CD33 Chimeric Antigen Receptor T Cell Therapy and Hypomethylating Agent Against Acute Myeloid Leukemia

Tongyuan Xue, MD, Marissa Del Real, PhD, Emanuela Marcucci, Candida Toribio, Sonia Maryam Setayesh, Stephen J Forman, MD, David A Horne, PhD, Lihua E Budde, MD PhD

Blood (2019) 134 (Supplement_1): 1383.

https://doi.org/10.1182/blood-2019-121486

Published: 2019

Journal Articles

Loss of KLF6 Recapitulates Molecular and Functional Changes Associated with Aging in Human Hematopoietic Stem and Progenitor Cells

Alejandro Roisman, PhD, Emmalee R. Adelman, BA, Hsuan-Ting Huang, PhD, Dean Wade, Daniel Bilbao, Maria E. Figueroa, MD

Blood (2019) 134 (Supplement_1): 447.

https://doi.org/10.1182/blood-2019-130800

Published: 2019

Journal Articles

Exploiting an Anti-CD3/CD33 Bispecific Antibody to Redirect Donor T Cells Against HLA Loss Leukemia Relapses

Pier Edoardo Rovatti, MD, Laura Zito, MSc, Eleonora Draghi, MSc, Monika Herrmann, PhD, Anetta Marcinek, MSc, Bettina Brauchle, MSc, Cesare Covino, MSc, Mattia Di Bono, MSc, Matteo Giovanni Carrabba, MD, Massimo Bernardi, MD, Karl-Peter Hopfner, PhD, Cristina Toffalori, PhD, Fabio Ciceri, MD, Marion Subklewe, MD, Luca Vago, MD PhD

Blood (2019) 134 (Supplement_1): 513.

https://doi.org/10.1182/blood-2019-126641

Published: 2019

Journal Articles

Ibrutinib Treatment in CLL Patients Improves T Cell Function and Blinatumomab Redirected Cytotoxicity

Meixiao Long, MD, Erich Williams, Clara Berard, Carolyn Cheney, BS, Eileen Hu, BS, Seema A. Bhat, MD, Kerry A. Rogers, MD, Jennifer Woyach, MD, Natarajan Muthusamy, DVM,PhD, John C. Byrd, MD

Blood (2019) 134 (Supplement_1): 1049.

https://doi.org/10.1182/blood-2019-125417

Published: 2019

Journal Articles

Impact of p53 Knock-Down on T-Cell Proliferation and T-Cell Mediated Cytotoxicity Against AML Cell Lines Mediated By a CD33 Specific BiTE ® Antibody Construct

Lea Pawlowsky, Bettina Brauchle, MSc, Maryam Kazerani Pasikhani, Ana Ogrinc Wagner, PhD, Veit Bücklein, MD, Felix S. Lichtenegger, MD, Roman Kischel, MD, Klaus H. Metzeler, MD, Karsten Spiekermann, MD, Michael Andreeff, MD PhD, Naval G. Daver, MD, Michael von Bergwelt, Marion Subklewe, MD

Blood (2019) 134 (Supplement_1): 1265.

https://doi.org/10.1182/blood-2019-122415

Published: 2019

Journal Articles

Targeted Inhibition of the NUP98-NSD1 Fusion Oncogene in AML

Sagarajit Mohanty, MSc, Nidhi Jyotsana, PhD, Amit Sharma, PhD, Basem Othman, Arnold Kloos, PhD, Madhvi Mandhania, MSc, Renate Schottmann, Euan Ramsay, PhD, Hans- Peter Vornlocher, PhD, Arnold Ganser, MD, Felicitas Thol, MD, Michael Heuser, MD

Blood (2019) 134 (Supplement_1): 2545.

https://doi.org/10.1182/blood-2019-123709

Published: 2019

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

How I treat pediatric acute myeloid leukemia

Cryptic insertion of KMT2A , a rare t(9;11) variant

CLEC12A and CD33 coexpression as a preferential target for pediatric AML combinatorial immunotherapy

Immunogenomic identification and characterization of granulocytic myeloid-derived suppressor cells in multiple myeloma

Mutational profile and benefit of gemtuzumab ozogamicin in acute myeloid leukemia

How I treat acute myeloid leukemia in the era of new drugs

Establishment of a Spontaneous Stromal Microenvironment from Cord Blood Supports Human Dynamic Erythropoietic Temporal Maturation in Long-Term Serum- and Cytokine-Free 3D Cultures and Reveals a Distinct CD44 hi Population

Novel CD33 Antibodies Unravel Localization, Biology, and Therapeutic Implications of CD33 Isoforms

Phase 1 First-in-Human Trial of AMV564, a Bivalent Bispecific (2:2) CD33/CD3 T-Cell Engager, in Patients with Relapsed/Refractory Acute Myeloid Leukemia (AML)

Preliminary Results from a Phase 1 First-in-Human Study of AMG 673, a Novel Half-Life Extended (HLE) Anti-CD33/CD3 BiTE ® (Bispecific T-Cell Engager) in Patients with Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML)

Characterization of Immune Cells Producing Regulatory Cytokines That Mediate Engraftment in Sickle Cell Disease Patients after Haploidentical Peripheral Blood Stem Cell Transplantation

Chimeric Antigen Receptor Modified Memory-like (CAR-ML) NK Cells Exhibit Potent Responses to NK-Resistant Tumors

Addition of the PARP Inhibitor, Talazoparib, to Gemtuzumab Ozogamicin Significantly Enhances Anti-Leukemic Activity in Human CD33+ Acute Myeloid Leukemia

Preliminary Lasso Regression Analysis Identifies DNA-Damage Gene Expression Signature Predictive of Clinical Outcomes in Patients Using Gemtuzumab Ozogamicin

Checkpoint Blockade in Combination with CD33 Chimeric Antigen Receptor T Cell Therapy and Hypomethylating Agent Against Acute Myeloid Leukemia

Loss of KLF6 Recapitulates Molecular and Functional Changes Associated with Aging in Human Hematopoietic Stem and Progenitor Cells

Exploiting an Anti-CD3/CD33 Bispecific Antibody to Redirect Donor T Cells Against HLA Loss Leukemia Relapses

Ibrutinib Treatment in CLL Patients Improves T Cell Function and Blinatumomab Redirected Cytotoxicity

Impact of p53 Knock-Down on T-Cell Proliferation and T-Cell Mediated Cytotoxicity Against AML Cell Lines Mediated By a CD33 Specific BiTE ® Antibody Construct

Targeted Inhibition of the NUP98-NSD1 Fusion Oncogene in AML

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only